Metropolitan Life Insurance CO Eq Rx, Inc. Transaction History

Metropolitan Life Insurance CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$1.61 - $1.96 $10,275 - $12,508	6,382 Added 56.01%	17,777 $33,000
Q1 2023 May 15, 2023	SELL	$1.8 - $2.83 $2,223 - $3,495	-1,235 Reduced 9.78%	11,395 $22,000
Q4 2022 Jun 14, 2023	BUY	$2.05 - $5.5 $2,531 - $6,792	1,235 Added 10.84%	12,630 $31.1 Million
Q3 2022 Jun 14, 2023	BUY	$0.94 - $5.99 $1,160 - $7,397	1,235 Added 10.84%	12,630 $62.5 Million
Q3 2022 Mar 30, 2023	BUY	$0.94 - $5.99 $3,725 - $23,738	3,963 Added 45.73%	12,630 $62,000
Q3 2022 Nov 14, 2022	BUY	$0.94 - $5.99 $3,725 - $23,738	3,963 Added 45.73%	12,630 $63,000
Q2 2022 Jun 20, 2023	SELL	$3.2 - $5.69 $8,729 - $15,522	-2,728 Reduced 23.94%	8,667 $40,000
Q2 2022 Mar 30, 2023	SELL	$3.2 - $5.69 $12,681 - $22,549	-3,963 Reduced 31.38%	8,667 $40,000
Q2 2022 Aug 11, 2022	BUY	$3.2 - $5.69 $27,734 - $49,315	8,667 New	8,667 $41,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.